Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation

In clinical trials with early Alzheimer’s patients, administration of anti-amyloid antibodies reduced amyloid deposits, suggesting that immunotherapies may be promising disease-modifying interventions against Alzheimer’s disease (AD). Specific forms of amyloid beta (Aβ) peptides, for example post-tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hettmann, Thore, Gillies, Stephen D., Kleinschmidt, Martin, Piechotta, Anke, Makioka, Koki, Lemere, Cynthia A., Schilling, Stephan, Rahfeld, Jens-Ulrich, Lues, Inge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040040/
https://www.ncbi.nlm.nih.gov/pubmed/32094456
http://dx.doi.org/10.1038/s41598-020-60319-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040040/
https://www.ncbi.nlm.nih.gov/pubmed/32094456
http://dx.doi.org/10.1038/s41598-020-60319-5

Ejemplares similares